XSpray Pharma AB (STU:6XP) Cyclically Adjusted FCF per Share: €-0.67 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6XP XSpray Pharma AB STU:6XP
40 GF Score
Price €1.40
! 1 Warning Sign
View Full Analysis

What is XSpray Pharma AB Cyclically Adjusted FCF per Share?

XSpray Pharma AB STU:6XP -4.51% 40 Cyclically Adjusted FCF per Share is €-0.67 as of Mar. 2026. GuruFocus rates STU:6XP with a GF Score™ of 40/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

XSpray Pharma AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.071. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.67 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-04), XSpray Pharma AB's current stock price is €1.396. XSpray Pharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.67. XSpray Pharma AB's Cyclically Adjusted Price-to-FCF of today is .


XSpray Pharma AB  (STU:6XP) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


XSpray Pharma AB Cyclically Adjusted FCF per Share Related Terms


XSpray Pharma AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for XSpray Pharma AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XSpray Pharma AB Cyclically Adjusted FCF per Share Chart

XSpray Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XSpray Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.67

STU:6XP vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, XSpray Pharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XSpray Pharma AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's Cyclically Adjusted Price-to-FCF falls into.


STU:6XP
40GF Score
XSpray Pharma AB STU:6XP
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XSpray Pharma AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, XSpray Pharma AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.071/133.5600*133.5600
=-0.071

Current CPI (Mar. 2026) = 133.5600.

XSpray Pharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 0.000 100.276 0.000
201609 -0.040 101.138 -0.053
201612 -0.078 102.022 -0.102
201703 -0.120 102.022 -0.157
201706 -0.070 102.752 -0.091
201709 0.020 103.279 0.026
201712 -0.163 103.793 -0.210
201803 -0.069 103.962 -0.089
201806 -0.111 104.875 -0.141
201809 -0.091 105.679 -0.115
201812 -0.147 105.912 -0.185
201903 -0.163 105.886 -0.206
201906 -0.173 106.742 -0.216
201909 -0.178 107.214 -0.222
201912 -0.198 107.766 -0.245
202003 -0.187 106.563 -0.234
202006 -0.182 107.498 -0.226
202009 -0.169 107.635 -0.210
202012 -0.174 108.296 -0.215
202103 -0.179 108.360 -0.221
202106 -0.192 108.928 -0.235
202109 -0.156 110.338 -0.189
202112 -0.175 112.486 -0.208
202203 -0.318 114.825 -0.370
202206 -0.227 118.384 -0.256
202209 -0.216 122.296 -0.236
202212 -0.233 126.365 -0.246
202303 -0.219 127.042 -0.230
202306 -0.255 129.407 -0.263
202309 -0.251 130.224 -0.257
202312 -0.143 131.912 -0.145
202403 -0.163 132.205 -0.165
202406 -0.188 132.716 -0.189
202409 -0.128 132.304 -0.129
202412 -0.197 132.987 -0.198
202503 -0.190 132.825 -0.191
202506 -0.117 133.699 -0.117
202509 -0.113 133.480 -0.113
202512 -0.092 133.390 -0.092
202603 -0.071 133.560 -0.071

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.67 mean?
XSpray Pharma AB (STU:6XP) has a Cyclically Adjusted FCF per Share of €-0.67 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on XSpray Pharma AB and its competitors.
Is XSpray Pharma AB's Cyclically Adjusted FCF per Share too high?
XSpray Pharma AB's current Cyclically Adjusted FCF per Share is €-0.67. Overall, XSpray Pharma AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does XSpray Pharma AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
XSpray Pharma AB's Cyclically Adjusted FCF per Share of €-0.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on XSpray Pharma AB and its competitors. XSpray Pharma AB's current Cyclically Adjusted FCF per Share is €-0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XSpray Pharma AB stock overvalued right now?
XSpray Pharma AB (STU:6XP) has a current Cyclically Adjusted FCF per Share of €-0.67. The current Cyclically Adjusted FCF per Share is €-0.67. XSpray Pharma AB's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For XSpray Pharma AB (STU:6XP), the current Cyclically Adjusted FCF per Share is €-0.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XSpray Pharma AB Business Description

Other Exchanges XSPRAY:Sweden0GHZ:UK
Address Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
40GF Score

Get the complete analysis for STU:6XP

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.40
Price